| Wang Qin,Yu Yanjun,Wang Xiunan,et al.Application of independent three-dimensional dose verification system ArcherQA in craniospinal irradiation[J].Chinese Journal of Radiological Medicine and Protection,2026,46(4):382-388 |
| Application of independent three-dimensional dose verification system ArcherQA in craniospinal irradiation |
| Received:February 11, 2025 |
| DOI：10.3760/cma.j.cn112271-20250211-00048 |
| KeyWords:Independent three-dimensional dose verification system|ArcherQA|Craniospinal irradiation|Dose verification |
| FundProject:北京市计划专项课题(Z181100001718011) |
| Author Name | Affiliation | E-mail | | Wang Qin | Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China | | | Yu Yanjun | Department of Radiation Oncology, Seventh Medical Center, Chinese PLA General Hospital, Beijing 100007, China | | | Wang Xiunan | Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China | | | Ni Wenjie | Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China | | | Zhang Fuli | Department of Radiation Oncology, Seventh Medical Center, Chinese PLA General Hospital, Beijing 100007, China | radiozfli@163.com | | Mu Xiaofeng | Department of Radiation Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China | |
|
| Hits: 3377 |
| Download times: 42 |
| Abstract:: |
| Objective To assess the clinical application value of the ArcherQA independent three-dimensional dose verification system in craniospinal irradiation (CSI) delivered by a linear accelerator (LA) and a helical tomotherapy system (HT) Methods Totally 40 patients receiving CSI in Beijing Shijitan Hospital, Capital Medical University from January 2023 to January 2024 were included in this study. Twenty plans were designed using the Eclipse treatment planning system (TPS) and delivered on an LA (also referred to as the LA plans), with dose verification performed using Portal Dosimetry (PD) and ArcherQA. Another twenty plans were designed utilizing the Precision TPS and delivered on an HT (also referred to as the HT plans), with dose verified using the Matrixx ionization chamber array and ArcherQA. The γ-pass rates calculated by ArcherQA under different γ criteria (3%/3 mm, 2%/3 mm, 3%/2 mm, 2%/2 mm, TH=10%) were compared with those measured using PD and Matrixx. The differences in doses to target volumes and organs at risk (OARs) between ArcherQA and TPSs were analyzed. Results The ArcherQA verification result showed that the global γ pass rates of both the LA and HT plans exceeded 95%. Under the most stringent criterion of 2%/2 mm, the γ pass rates of the overall target volumes were relatively low: 87.9 (78.6, 91.7) and 92.6 (81.8, 97.4) for LA and the HT plans, respectively. In contrast, the γ pass rates under other criteria all exceeded 97%. The head-neck section, spinal section, and field overlap regions Overlap1 and Overlap2 showed the lowest γ pass rates under the 2%/2 mm criterion. Overall, the HT plans demonstrated higher γ pass rates than the LA plans. The dosimetric comparison revealed that in the LA plans, the differences in Dmean of planning target volume (PTV), Overlap1, and Overlap2 were insignificant (P > 0.05). For these plans, the Dmax of PTV calculated by ArcherQA was 1.53 Gy higher than that from the Eclipse TPS (95% CI: -1.93 to 1.12, P < 0.001), while D95% was 0.36 Gy lower (95% CI: -0.45 to -0.27, P < 0.001). In the HT plans, the D95% of PTV calculated by ArcherQA was 0.39 Gy lower than that determined using the Precision TPS (95% CI: -0.49 to -0.29, P < 0.001). Doses to all OARs met clinical requirements. The comparison of γ-pass rates indicated that PD generally yielded higher γ pass rates than ArcherQA calculations (P < 0.001). Compared to Matrixx, ArcherQA showed higher γ pass rates in the head-neck section (P < 0.005), but no significant difference was observed in the γ pass rate in the spinal section (P > 0.05). Conclusions The ArcherQA system enables both the rapid reconstruction of the three-dimensional dose distributions based on patients'CT images and dose-volume histogram analyses. This system achieves integrated dose verification for CSI without consuming additional device time, thereby significantly improving work efficiency. |
| HTML View Full Text View/Add Comment Download reader |
| Close |
|
|
|
